Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

This study has been completed.
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc. Identifier:
First received: August 13, 2002
Last updated: June 23, 2005
Last verified: September 2002
Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.

Condition Intervention Phase
Congestive Heart Failure
Drug: Tolvaptan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Multi-Center, Double-Blind Study to Compare the Effects of 30mg Qd Versus 15 Mg Bid of Tolvaptan in Congestive Heart Failure Patients

Resource links provided by NLM:

Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Estimated Enrollment: 40
Study Start Date: May 2002
Estimated Study Completion Date: September 2002

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
History of CHF
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00043771

United States, California
Central Cardiology Medical Clinic
Bakersfield, California, United States
University of California-San Diego
San Diego, California, United States
United States, Florida
University of Miami/Jackson Memorial Hospital
Miami, Florida, United States
United States, Louisiana
Medical Research Institute
Slidell, Louisiana, United States
United States, Maine
Androscoggin Cardiology Associates
Auburn, Maine, United States
United States, Missouri
University of Missouri-Kansas City School of Medicine
Kansas City, Missouri, United States
Saint Louis University
St. Louis, Missouri, United States
United States, Oklahoma
Cardiology of Oklahoma
Tulsa, Oklahoma, United States
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information Identifier: NCT00043771     History of Changes
Other Study ID Numbers: 156-01-231
Study First Received: August 13, 2002
Last Updated: June 23, 2005

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs processed this record on May 25, 2017